A negative vote in the House seems baked-in at this point. What concerns me as a biotech investor is that the inability to pass healthcare legislation could make it harder for Congress to pass US corporate-tax reform, due to the peculiarities of the Congressional budgeting process.
If there are diminished prospects for US corporate-tax reform, much of the gain in the broad stock market (including many drug/biotech stocks) since the US presidential election could evaporate.
Hi Mr Salmon: Looks like they don't have the votes to pass it as is. That bill offers less coverage to less people at a greater cost. Trump said pass it as is or forget it. Given that, it's a major defeat for the president who's pronouncements have driven the bios in general down in PPS. So . it's probably good for us, especially if we can ever actually get a product on the market.
News 
Market Data 
Discover 
